{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:30:00Z","timestamp":1786984200026,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lions foundation for cancer research"},{"name":"Selander foundation"},{"name":"S\u00f6derberg foundation"},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN2017\/348"],"award-info":[{"award-number":["CAN2017\/348"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumours that compose 1\u20132% of all pancreatic tumours. Patients with metastatic grade 3 neoplasia are usually treated with chemotherapy but have a poor progression-free and overall survival. According to the WHO 2017 classification, they are divided into neuroendocrine tumours (NETs) G3 and neuroendocrine carcinomas (NECs). Despite the new classification, new diagnostic and prognostic biomarkers are needed to sub-categorise the patients and to help guide therapy decisions. Blood from 42 patients and 42 healthy controls were screened for the presence of 92 proteins with the Immuno-Oncology panel using the Proximity Extension Assay provided by Olink Biosciences. Immunohistochemical staining of FAS ligand (FASLG) was performed on 16 patient tumour specimens using a commercial antibody. Fifty-four out of 87 evaluable proteins differed significantly in concentration between blood from patients and blood from healthy controls. FASLG was the only protein for which the concentration in blood was significantly lower in patients compared to controls and the levels correlated negatively to Ki-67 index. Seven of 14 evaluable PanNEN G3 specimens showed FASLG immunoreactivity in the tumour cells while there was scattered immunoreactivity in immune cells. Positive FASLG immunoreactivity correlated to well-differentiated morphology. FASLG concentration in blood was significantly lower in patients with pancreatic NENs G3 compared to controls, and the expression in tumour tissue was variable. Furthermore, FASLG was negatively correlated to Ki-67 and was more frequently expressed in well-differentiated tumours. Taken together, these results may suggest a role of FASLG in PanNENs.<\/jats:p>","DOI":"10.1038\/s41598-020-67670-7","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T10:03:57Z","timestamp":1593511437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3"],"prefix":"10.1038","volume":"10","author":[{"given":"Abir Salwa","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurel","family":"Perren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lindskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Welin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halfdan","family":"Sorbye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Gr\u00f6nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Tiensuu","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"67670_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bpg.2013.01.006","volume":"26","author":"M Fraenkel","year":"2012","unstructured":"Fraenkel, M., Kim, M. K., Faggiano, A. & Valk, G. D. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract. Res. Clin. Gastroenterol. 26, 691\u2013703. https:\/\/doi.org\/10.1016\/j.bpg.2013.01.006 (2012).","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"67670_CR2","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1677\/ERC-07-0221","volume":"15","author":"TR Halfdanarson","year":"2008","unstructured":"Halfdanarson, T. R., Rubin, J., Farnell, M. B., Grant, C. S. & Petersen, G. M. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr. Relat. Cancer 15, 409\u2013427. https:\/\/doi.org\/10.1677\/ERC-07-0221 (2008).","journal-title":"Endocr. Relat. Cancer"},{"key":"67670_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, J. C. et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26, 3063\u20133072. https:\/\/doi.org\/10.1200\/JCO.2007.15.4377 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 7","key":"67670_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/annonc\/mdq290","volume":"21","author":"KE Oberg","year":"2010","unstructured":"Oberg, K. E. Gastrointestinal neuroendocrine tumors. Ann. Oncol. 21(Suppl 7), 72\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdq290 (2010).","journal-title":"Ann. Oncol."},{"key":"67670_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","volume":"40","author":"LH Tang","year":"2016","unstructured":"Tang, L. H., Basturk, O., Sue, J. J. & Klimstra, D. S. A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am. J. Surg. Pathol. 40, 1192\u20131202. https:\/\/doi.org\/10.1097\/PAS.0000000000000662 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"67670_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000445165","volume":"104","author":"M Milione","year":"2017","unstructured":"Milione, M. et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104, 85\u201393. https:\/\/doi.org\/10.1159\/000445165 (2017).","journal-title":"Neuroendocrinology"},{"key":"67670_CR7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1634\/theoncologist.2015-0476","volume":"21","author":"R Coriat","year":"2016","unstructured":"Coriat, R., Walter, T., Terris, B., Couvelard, A. & Ruszniewski, P. Gastroenteropancreatic well-differentiated grade 3 neuroendocrine tumors: review and position statement. Oncologist 21, 1191\u20131199. https:\/\/doi.org\/10.1634\/theoncologist.2015-0476 (2016).","journal-title":"Oncologist"},{"key":"67670_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ecl.2018.05.001","volume":"47","author":"H Sorbye","year":"2018","unstructured":"Sorbye, H., Baudin, E. & Perren, A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond. Endocrinol. Metab. Clin. N. Am. 47, 683\u2013698. https:\/\/doi.org\/10.1016\/j.ecl.2018.05.001 (2018).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"67670_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/Pcr.0000000000000211","volume":"22","author":"G Kloppel","year":"2017","unstructured":"Kloppel, G. et al. Pancreatic neuroendocrine tumors: update on the new World Health Organization Classification. AJSP Rev. Rep. 22, 233\u2013239. https:\/\/doi.org\/10.1097\/Pcr.0000000000000211 (2017).","journal-title":"AJSP Rev. Rep."},{"key":"67670_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","volume":"39","author":"JR Strosberg","year":"2010","unstructured":"Strosberg, J. R. et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39, 799\u2013800. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ebb56f (2010).","journal-title":"Pancreas"},{"key":"67670_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3109\/0284186X.2014.941999","volume":"53","author":"ET Janson","year":"2014","unstructured":"Janson, E. T. et al. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 53, 1284\u20131297. https:\/\/doi.org\/10.3109\/0284186X.2014.941999 (2014).","journal-title":"Acta Oncol."},{"key":"67670_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","volume":"103","author":"R Garcia-Carbonero","year":"2016","unstructured":"Garcia-Carbonero, R. et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103, 186\u2013194. https:\/\/doi.org\/10.1159\/000443172 (2016).","journal-title":"Neuroendocrinology"},{"key":"67670_CR13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1756283X13493878","volume":"6","author":"AI Vinik","year":"2013","unstructured":"Vinik, A. I. & Raymond, E. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Ther. Adv. Gastroenterol. 6, 396\u2013411. https:\/\/doi.org\/10.1177\/1756283X13493878 (2013).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"67670_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","volume":"22","author":"LH Tang","year":"2016","unstructured":"Tang, L. H. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer. Res. 22, 1011\u20131017. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0548 (2016).","journal-title":"Clin. Cancer. Res."},{"key":"67670_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11154-019-09508-w","volume":"20","author":"G Boons","year":"2019","unstructured":"Boons, G., Vandamme, T., Peeters, M., Van Camp, G. & Op de Beeck, K. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: moving towards liquid biopsies. Rev. Endocr. Metab. Disord. 20, 333\u2013351. https:\/\/doi.org\/10.1007\/s11154-019-09508-w (2019).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"67670_CR16","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192 (2014).","journal-title":"PLoS ONE"},{"key":"67670_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/cdd.2015.3","volume":"22","author":"ME Peter","year":"2015","unstructured":"Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 549\u2013559. https:\/\/doi.org\/10.1038\/cdd.2015.3 (2015).","journal-title":"Cell Death Differ."},{"key":"67670_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0092-8674(91)90614-5","volume":"66","author":"N Itoh","year":"1991","unstructured":"Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen FAS can mediate apoptosis. Cell 66, 233\u2013243 (1991).","journal-title":"Cell"},{"key":"67670_CR19","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.4049\/jimmunol.154.8.3806","volume":"154","author":"T Suda","year":"1995","unstructured":"Suda, T. et al. Expression of the FAS ligand in cells of T cell lineage. J. Immunol. 154, 3806\u20133813 (1995).","journal-title":"J. Immunol."},{"key":"67670_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1126\/science.7518614","volume":"265","author":"D Kagi","year":"1994","unstructured":"Kagi, D. et al. FAS and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265, 528\u2013530 (1994).","journal-title":"Science"},{"key":"67670_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/0092-8674(93)90326-L","volume":"75","author":"T Suda","year":"1993","unstructured":"Suda, T., Takahashi, T., Golstein, P. & Nagata, S. Molecular cloning and expression of the FAS ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169\u20131178 (1993).","journal-title":"Cell"},{"key":"67670_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","volume":"11","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255\u2013260 (1999).","journal-title":"Curr. Opin. Cell Biol."},{"key":"67670_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1046\/j.1440-1711.1999.00837.x","volume":"77","author":"P Waring","year":"1999","unstructured":"Waring, P. & Mullbacher, A. Cell death induced by the FAS\/FAS ligand pathway and its role in pathology. Immunol. Cell Biol. 77, 312\u2013317. https:\/\/doi.org\/10.1046\/j.1440-1711.1999.00837.x (1999).","journal-title":"Immunol. Cell Biol."},{"key":"67670_CR24","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/cdd.2015.25","volume":"22","author":"ME Peter","year":"2015","unstructured":"Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 885\u2013886. https:\/\/doi.org\/10.1038\/cdd.2015.25 (2015).","journal-title":"Cell Death Differ."},{"key":"67670_CR25","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/cncr.27937","volume":"119","author":"TK Owonikoko","year":"2013","unstructured":"Owonikoko, T. K. et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer 119, 1503\u20131511. https:\/\/doi.org\/10.1002\/cncr.27937 (2013).","journal-title":"Cancer"},{"key":"67670_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.surg.2012.02.011","volume":"152","author":"NA Hamilton","year":"2012","unstructured":"Hamilton, N. A. et al. Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms. Surgery 152, 107\u2013113. https:\/\/doi.org\/10.1016\/j.surg.2012.02.011 (2012).","journal-title":"Surgery"},{"key":"67670_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.14670\/HH-15.851","volume":"15","author":"WH Liu","year":"2000","unstructured":"Liu, W. H. & Wang, D. G. Apoptosis regulating genes in neuroendocrine tumors. Histol. Histopathol. 15, 851\u2013859. https:\/\/doi.org\/10.14670\/HH-15.851 (2000).","journal-title":"Histol. Histopathol."},{"key":"67670_CR28","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1002\/cncr.10549","volume":"94","author":"WV Bernstorff","year":"2002","unstructured":"Bernstorff, W. V. et al. FAS (CD95\/APO-1) and FAS ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 94, 2552\u20132560. https:\/\/doi.org\/10.1002\/cncr.10549 (2002).","journal-title":"Cancer"},{"key":"67670_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00000658-200003000-00010","volume":"231","author":"M Kornmann","year":"2000","unstructured":"Kornmann, M., Ishiwata, T., Kleeff, J., Beger, H. G. & Korc, M. FAS and Fas-ligand expression in human pancreatic cancer. Ann. Surg. 231, 368\u2013379. https:\/\/doi.org\/10.1097\/00000658-200003000-00010 (2000).","journal-title":"Ann. Surg."},{"key":"67670_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/00006676-200003000-00003","volume":"20","author":"M Kornmann","year":"2000","unstructured":"Kornmann, M., Ishiwata, T., Maruyama, H., Beger, H. G. & Korc, M. Coexpression of FAS and FAS-ligand in chronic pancreatitis: correlation with apoptosis. Pancreas 20, 123\u2013128. https:\/\/doi.org\/10.1097\/00006676-200003000-00003 (2000).","journal-title":"Pancreas"},{"key":"67670_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41420-019-0217-z","volume":"5","author":"PM Trivedi","year":"2019","unstructured":"Trivedi, P. M. et al. Soluble FAS ligand is not required for pancreatic islet inflammation or beta-cell destruction in non-obese diabetic mice. Cell Death Discov. 5, 136 (2019).","journal-title":"Cell Death Discov."},{"key":"67670_CR32","doi-asserted-by":"publisher","first-page":"S652","DOI":"10.21037\/tcr.2017.05.32","volume":"6","author":"C Lu","year":"2017","unstructured":"Lu, C. & Liu, K. Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy. Transl. Cancer Res. 6, S652\u2013S654 (2017).","journal-title":"Transl. Cancer Res."},{"key":"67670_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nm.3442","volume":"20","author":"S Afshar-Sterle","year":"2014","unstructured":"Afshar-Sterle, S. et al. FAS ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas. Nat. Med. 20, 283\u2013290. https:\/\/doi.org\/10.1038\/nm.3442 (2014).","journal-title":"Nat. Med."},{"key":"67670_CR34","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1158\/0008-5472.CAN-05-1462","volume":"65","author":"AE Ryan","year":"2005","unstructured":"Ryan, A. E., Shanahan, F., O\u2019Connell, J. & Houston, A. M. Addressing the \u201cFAS counterattack\u201d controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res. 65, 9817\u20139823. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1462 (2005).","journal-title":"Cancer Res."},{"key":"67670_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/35037728","volume":"407","author":"PH Krammer","year":"2000","unstructured":"Krammer, P. H. CD95\u2019s deadly mission in the immune system. Nature 407, 789\u2013795. https:\/\/doi.org\/10.1038\/35037728 (2000).","journal-title":"Nature"},{"key":"67670_CR36","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.4049\/jimmunol.160.11.5669","volume":"160","author":"MW Bennett","year":"1998","unstructured":"Bennett, M. W. et al. The FAS counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with FAS ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669\u20135675 (1998).","journal-title":"J. Immunol."},{"key":"67670_CR37","first-page":"3560","volume":"6","author":"K Okada","year":"2000","unstructured":"Okada, K. et al. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer. Res. 6, 3560\u20133564 (2000).","journal-title":"Clin. Cancer. Res."},{"key":"67670_CR38","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1054\/bjoc.1999.1073","volume":"82","author":"S Munakata","year":"2000","unstructured":"Munakata, S. et al. Expressions of FAS ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br. J. Cancer 82, 1446\u20131452 (2000).","journal-title":"Br. J. Cancer"},{"key":"67670_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ijc.11392","volume":"107","author":"A Houston","year":"2003","unstructured":"Houston, A. et al. FAS ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int. J. Cancer 107, 209\u2013214. https:\/\/doi.org\/10.1002\/ijc.11392 (2003).","journal-title":"Int. J. Cancer"},{"key":"67670_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2478\/v10042-010-0058-3","volume":"48","author":"A Pryczynicz","year":"2010","unstructured":"Pryczynicz, A., Guzinska-Ustymowicz, K. & Kemona, A. FAS\/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem. Cytobiol. 48, 425\u2013429. https:\/\/doi.org\/10.2478\/v10042-010-0058-3 (2010).","journal-title":"Folia Histochem. Cytobiol."},{"key":"67670_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/his.13408","volume":"72","author":"AD Singhi","year":"2018","unstructured":"Singhi, A. D. & Klimstra, D. S. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology 72, 168\u2013177. https:\/\/doi.org\/10.1111\/his.13408 (2018).","journal-title":"Histopathology"},{"key":"67670_CR42","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1242\/jcs.00739","volume":"116","author":"S Haupt","year":"2003","unstructured":"Haupt, S., Berger, M., Goldberg, Z. & Haupt, Y. Apoptosis\u2014the p53 network. J. Cell. Sci. 116, 4077\u20134085. https:\/\/doi.org\/10.1242\/jcs.00739 (2003).","journal-title":"J. Cell. Sci."},{"key":"67670_CR43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/cdd.2017.169","volume":"25","author":"BJ Aubrey","year":"2018","unstructured":"Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J. & Strasser, A. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?. Cell Death Differ. 25, 104\u2013113. https:\/\/doi.org\/10.1038\/cdd.2017.169 (2018).","journal-title":"Cell Death Differ."},{"key":"67670_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/sj.cr.7290176","volume":"13","author":"LJ Metheny-Barlow","year":"2003","unstructured":"Metheny-Barlow, L. J. & Li, L. Y. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res. 13, 309\u2013317. https:\/\/doi.org\/10.1038\/sj.cr.7290176 (2003).","journal-title":"Cell Res."},{"key":"67670_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/35059110","volume":"409","author":"O Mandelboim","year":"2001","unstructured":"Mandelboim, O. et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409, 1055\u20131060. https:\/\/doi.org\/10.1038\/35059110 (2001).","journal-title":"Nature"},{"key":"67670_CR46","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.ejca.2011.11.032","volume":"48","author":"M Kawamura","year":"2012","unstructured":"Kawamura, M. et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur. J. Cancer 48, 2244\u20132251. https:\/\/doi.org\/10.1016\/j.ejca.2011.11.032 (2012).","journal-title":"Eur. J. Cancer"},{"key":"67670_CR47","doi-asserted-by":"publisher","first-page":"32401","DOI":"10.1074\/jbc.272.51.32401","volume":"272","author":"Y Chicheportiche","year":"1997","unstructured":"Chicheportiche, Y. et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272, 32401\u201332410. https:\/\/doi.org\/10.1074\/jbc.272.51.32401 (1997).","journal-title":"J. Biol. Chem."},{"key":"67670_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/s1074-7613(01)00232-1","volume":"15","author":"SR Wiley","year":"2001","unstructured":"Wiley, S. R. et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837\u2013846. https:\/\/doi.org\/10.1016\/s1074-7613(01)00232-1 (2001).","journal-title":"Immunity"},{"key":"67670_CR49","doi-asserted-by":"publisher","DOI":"10.3791\/3620","author":"C Kampf","year":"2012","unstructured":"Kampf, C., Olsson, I., Ryberg, U., Sjostedt, E. & Ponten, F. Production of tissue microarrays, immunohistochemistry staining and digitalization within the human protein atlas. J. Vis. Exp. https:\/\/doi.org\/10.3791\/3620 (2012).","journal-title":"J. Vis. Exp."},{"key":"67670_CR50","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics tissue-based map of the human proteome. Science 347, 1260419. https:\/\/doi.org\/10.1126\/science.1260419 (2015).","journal-title":"Science"},{"key":"67670_CR51","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.21037\/jtd.2017.05.34","volume":"9","author":"SY Chen","year":"2017","unstructured":"Chen, S. Y., Feng, Z. & Yi, X. A general introduction to adjustment for multiple comparisons. J. Thorac. Dis. 9, 1725\u20131729. https:\/\/doi.org\/10.21037\/jtd.2017.05.34 (2017).","journal-title":"J. Thorac. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67670-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67670-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67670-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:50:48Z","timestamp":1696312248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67670-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67670"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67670-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"2 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10639"}}